How does CX5's PB Ratio compare to its peers?

CX5 has negative equity and a Price-To-Book Ratio (-0.5x) compared to the peer average (0.7x).

How does CX5's PB Ratio compare vs other companies in the DE Biotechs Industry?

CX5 has negative equity and a Price-To-Book Ratio (-0.5x) compared to the European Biotechs industry average (2.5x).

What is CX5's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate CX5's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of CX5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate CX5's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

LadRx (BST:CX5) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CX5 Stock Overview

A biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. More details

CX5 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Earnings have grown 5.6% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap (€988K)

Makes less than USD$1m in revenue ($0)

Negative shareholders equity

Shares are highly illiquid

+ 2 more risks

LadRx Corporation Competitors

bioXXmed

XTRA:T5O

€863.1k

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€16.7m

4SC

DB:VSC

€50.2m

Price History & Performance

Summary of all time highs, changes and price drops for LadRx
Historical stock prices
Current Share Price	US$0.056
52 Week High	US$21.80
52 Week Low	US$0.056
Beta	1.71
11 Month Change	0%
3 Month Change	-99.00%
1 Year Change	-99.44%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-99.87%

Recent updates

Shareholder Returns

	CX5	DE Biotechs	DE Market
7D	0%	1.1%	1.3%
1Y	-99.4%	-18.5%	7.9%

Return vs Industry: CX5 underperformed the German Biotechs industry which returned -23.1% over the past year.

Return vs Market: CX5 underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is CX5's price volatile compared to industry and market?
CX5 volatility
CX5 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.7%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: CX5's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine CX5's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1985	3	Stephen Snowdy	www.ladrxcorp.com

LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer. Further, the company’s Linker Activated Drug Release technology platform consists of an organic backbone, as well as develops albumin companion diagnostic to identify patients with cancer.

LadRx Corporation Fundamentals Summary

How do LadRx's earnings and revenue compare to its market cap?
CX5 fundamental statistics
Market cap	€905.08k
Earnings (TTM)	-€4.03m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Is CX5 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CX5 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$4.40m
Earnings	-US$4.40m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-8.89
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did CX5 perform over the long term?

See historical performance and comparison

LadRx BST:CX5 Stock Report